Medicilon Helps iMBioRay's CAR-raNK Cell Therapy Approved Clinical Trial

Recently, IBR854 Cell Injection of iMBioRay (Hangzhou) Biomedical Co., Ltd. (iMBioRay) obtained the permission of the NMPA for clinical trials. IBR854 Injection is a universal off-the-shelf CAR-raNK cell product derived from allogeneic peripheral blood. The indication is the treatment of patients with unresectable locally advanced or metastatic solid tumors who currently have no or cannot tolerate standard treatment. It is the first non-gene-modified CAR-raNK cell therapy for solid tumors in China, and the world's first FIC (First in class) products.

Shanghai Medicilon Inc. (Medicilon), as a partner of IBR854 Cell Injection, provides efficient, high-quality and comprehensive preclinical research services (including pharmacokinetic studies and safety evaluation) in compliance with GLP regulations. The IBR854 Cell Injection is successfully approved at the end.

Medicilon cell immunotherapy drug service platform
Enabling the sustainable development of global cellular immunotherapy

Cellular immunotherapy is currently known as the most promising treatment for cancer. In recent years, China's cell therapy industry is booming, and the advent of innovative drugs represented by CAR-T cell therapy has endowed immune cell therapy with more potential.

Medicilon, as a one-stop biopharmaceutical preclinical comprehensive R&D service CRO in China, has always been at the forefront of advanced technology, and has built a one-stop research platform for the preclinical R&D of cellular immunotherapy drugs. Using a wealth of animal models and a variety of advanced analytical techniques, Medicilon could provide pharmacodynamic research, drug safety evaluation, and pharmacokinetic research for a variety of immunotherapeutic drugs including CAR-T, TCR-T, and CAR-NK, bioanalysis and other R&D services. Medicilon has completed several preclinical development projects of immunotherapy programs for clients worldwide.

The clinical approval of IBR854 injection means that China's NK cell therapy industry has taken a further step forward, which strongly proves the advantages and innovation capabilities of iMBioRay’s CAR-raNK cell technology platform, as well as the R&D service strength of Medicilon’s cell immunotherapy drug platform. Both parties accumulated valuable experience to develop more cellular immunotherapy drugs in the future.

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

阅读全文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the preclinical study of the antibody-drug-conjugate (ADC) DXC005, including the pharmacology study , DMPK study and the safety evaluation . Medicilon has previously completed integrated preclinical research on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

阅读全文

Shanghai Medicilon Inc.

搜索此博客